{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:10:46Z","timestamp":1769047846682,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In early 2020, no drug had proven efficacy to treat COVID-19 in-patients. This work aimed to describe COVID-19 treatment for in-patients worldwide until June, 2020. A PubMed search was performed with the terms \u201cretrospective observational study\u201d, \u201chospital\u201d, \u201ctreatment\u201d and \u201cCOVID\u201d to identify English-written studies describing treatments given to adult in-patients before June 30, 2020. The identified reports were analyzed, with data extracted regarding patient characteristics and treatments across continents and countries. Overall, 178 studies involving 181,510 patients in 28 countries were analyzed, including 484 patients from Africa, 36,840 from Asia, 69,088 from Europa and 68,524 from North America. The most prescribed drugs were hydroxychloroquine (64.3%, i.e. 41.9% of all patients), corticosteroids (31.0%, i.e. 21.0%) and lopinavir\/ritonavir (30.8%, i.e. 12.0%). Corticosteroids was used worldwide with similar rates in Asia, Europe and North America. Hydroxychloroquine dominated prescriptions in Africa, Europe and North America. Asia exhibited unique features: less frequent hydroxychloroquine use, higher oseltamivir use and exclusive use of umifenovir. In Europe, repurposed drugs prescription was the highest in Spain and Italy. Our study is not an exhaustive review of the literature on COVID-19 treatment of in-patients early in 2020 but is the first one to provide a comprehensive overview of COVID-19 treatment modalities in such a broad range of countries worldwide. Our work reveals high prescription rates but also heterogeneity across continents and countries in the treatment of COVID-19 in-patients worldwide. These findings emphasize the critical role of international collaboration in generating and disseminating reliable information for managing emerging diseases.<\/jats:p>","DOI":"10.1186\/s12879-025-12368-2","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:36:20Z","timestamp":1765964180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 treatment of hospital patients worldwide at the onset of the pandemic in 2020: a systematic review"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7282-6512","authenticated-orcid":false,"given":"Antoine","family":"Bosquet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Comlan","family":"Affo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Happe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Helfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Versini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"12368_CR1","unstructured":"WHO Coronavirus (COVID-19.) Dashboard [Internet]. [cit\u00e9 11 mars 2021]. Disponible sur: https:\/\/covid19.who.int"},{"key":"12368_CR2","doi-asserted-by":"crossref","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824\u201336.","DOI":"10.1001\/jama.2020.6019"},{"key":"12368_CR3","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;19(21):2030\u201340.","DOI":"10.1056\/NEJMoa2022926"},{"key":"12368_CR4","doi-asserted-by":"crossref","unstructured":"Repurposed Antiviral Drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"12368_CR5","doi-asserted-by":"publisher","unstructured":"Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19 \u2013 Preliminary Report [Internet]. medRxiv; 2020 [cit\u00e9 11 ao\u00fbt 2023]. p. 2020.06.22.20137273. Disponible sur: https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2020.06.22.20137273v1","DOI":"10.1101\/2020.06.22.20137273v1"},{"key":"12368_CR6","unstructured":"The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;6(13):1330\u201341."},{"key":"12368_CR7","doi-asserted-by":"publisher","first-page":"n433","DOI":"10.1136\/bmj.n433","volume":"372","author":"J Wise","year":"2021","unstructured":"Wise J. Covid-19: arthritis drug Tocilizumab reduces deaths in hospitalised patients, study shows. BMJ. 2021;372:n433.","journal-title":"BMJ 11 f\u00e9vr"},{"key":"12368_CR8","doi-asserted-by":"crossref","unstructured":"Bosquet A, Affo C, Plaisance L, Poenou G, Mortier E, Mah\u00e9 I. Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists. PLOS ONE. 2022;17(1):e0261843.","DOI":"10.1371\/journal.pone.0261843"},{"key":"12368_CR9","doi-asserted-by":"crossref","unstructured":"Prats-Uribe A, Sena AG, Lai LYH, Ahmed WUR, Alghoul H, Alser O, et al. Use of repurposed and adjuvant drugs in hospital patients with Covid-19: multinational network cohort study. BMJ. 2021;n1038.","DOI":"10.1136\/bmj.n1038"},{"issue":"24","key":"12368_CR10","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.3390\/jcm10245891","volume":"10","author":"M S\u00e1nchez-Rico","year":"2021","unstructured":"S\u00e1nchez-Rico M, Limosin F, Vernet R, Beeker N, Neuraz A, Blanco C, et al. Hydroxyzine use and mortality in patients hospitalized for COVID-19: A multicenter observational study. J Clin Med. 2021;10(24):5891.","journal-title":"J Clin Med Janv"},{"key":"12368_CR11","unstructured":"EPI-PHARE [Internet]. 2021 [cit\u00e9 29 sept 2023]. Covid-19: usage des m\u00e9dicaments - rapport 6. Disponible sur: https:\/\/www.epi-phare.fr\/rapports-detudes-et-publications\/covid-19-usage-des-medicaments-rapport-6\/"},{"key":"12368_CR12","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, van Meijgaard J, Mehra MR, Joseph J, O\u2019Donnell CJ, Warraich HJ. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States. JAMA. 2020;323(24):2524\u20136.","DOI":"10.1001\/jama.2020.9184"},{"issue":"35","key":"12368_CR13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.15585\/mmwr.mm6935a4","volume":"69","author":"L Bull-Otterson","year":"2020","unstructured":"Bull-Otterson L, Gray EB, Budnitz DS, Strosnider HM, Schieber LZ, Courtney J, et al. Hydroxychloroquine and chloroquine prescribing patterns by provider specialty following initial reports of potential benefit for COVID-19 Treatment - United States, January-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(35):1210\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep 4 Sept"},{"issue":"18","key":"12368_CR14","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s40265-020-01424-7","volume":"80","author":"KJ Lin","year":"2020","unstructured":"Lin KJ, Schneeweiss S, Tesfaye H, D\u2019Andrea E, Liu J, Lii J, et al. Pharmacotherapy for hospitalized patients with COVID-19: treatment patterns by disease severity. Drugs. 2020;80(18):1961\u201372.","journal-title":"Drugs d\u00e9c"},{"key":"12368_CR15","doi-asserted-by":"crossref","unstructured":"Gourieux B, Reisz F, Belmas AS, Danion F, Fourtage M, Nai T, et al. nov. Prescribing practices of lopinavir\/ritonavir, hydroxychloroquine and Azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital. Eur J Hosp Pharm Sci Pract. 2020;25.","DOI":"10.1136\/ejhpharm-2020-002449"},{"key":"12368_CR16","doi-asserted-by":"crossref","unstructured":"Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;382(25):2411\u20138.","DOI":"10.1056\/NEJMoa2012410"},{"key":"12368_CR17","doi-asserted-by":"crossref","unstructured":"Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020;323(24):2493\u2013502.","DOI":"10.1001\/jama.2020.8630"},{"key":"12368_CR18","doi-asserted-by":"crossref","unstructured":"Mah\u00e9vas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.","DOI":"10.1136\/bmj.m1844"},{"key":"12368_CR19","first-page":"m2263","volume":"369","author":"I Torjesen","year":"2020","unstructured":"Torjesen I. Covid-19: hydroxychloroquine does not benefit hospitalised patients, UK trial finds. BMJ. 2020;369:m2263.","journal-title":"BMJ 8 Juin"},{"issue":"10223","key":"12368_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","volume":"395","author":"CD Russell","year":"2020","unstructured":"Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473\u20135.","journal-title":"Lancet 15 f\u00e9vr"},{"key":"12368_CR21","doi-asserted-by":"crossref","unstructured":"Dagens A, Sigfrid L, Cai E, Lipworth S, Cheng V, Harris E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ. 2020;369:m1936.","DOI":"10.1136\/bmj.m1936"},{"issue":"10274","key":"12368_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","volume":"397","author":"Azithromycin in patients admitted","year":"2021","unstructured":"Azithromycin in patients admitted. To hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605\u201312.","journal-title":"Lancet 13 f\u00e9vr"},{"issue":"1","key":"12368_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cmi.2020.08.022","volume":"27","author":"T Fiolet","year":"2021","unstructured":"Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without Azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):19\u201327.","journal-title":"Clin Microbiol Infect 1 Janv"},{"issue":"1","key":"12368_CR24","first-page":"22","volume":"7","author":"X Xu","year":"2020","unstructured":"Xu X, Ong YK, Wang DY. Role of adjunctive treatment strategies in COVID-19 and a review of international and National clinical guidelines. Mil Med Res. 2020;7(1):22.","journal-title":"Mil Med Res 5 Mai"},{"issue":"10","key":"12368_CR25","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1007\/s12325-020-01460-5","volume":"37","author":"K Subramanian","year":"2020","unstructured":"Subramanian K, Nalli A, Senthil V, Jain S, Nayak A, Bhat A. Perspectives on the early quality of evidence guiding the therapeutic management of SARS-CoV-2: A systematic literature review. Adv Ther. 2020;37(10):4107\u201331.","journal-title":"Adv Ther 1 Oct"},{"key":"12368_CR26","unstructured":"HCSP. SARS-CoV-2: therapeutic recommendations [Internet]. Rapport de l\u2019HCSP. Paris: Haut Conseil de la Sant\u00e9 Publique; 2020 mars [cit\u00e9 11 mars 2021]. Disponible sur: https:\/\/www.hcsp.fr\/Explore.cgi\/avisrapportsdomaine?clefr=801"},{"issue":"4","key":"12368_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1345\/aph.1D390","volume":"38","author":"GT Schumock","year":"2004","unstructured":"Schumock GT, Walton SM, Park HY, Nutescu EA, Blackburn JC, Finley JM, et al. Factors that influence prescribing decisions. Ann Pharmacother. 2004;38(4):557\u201362.","journal-title":"Ann Pharmacother Avr"},{"key":"12368_CR28","unstructured":"Emergency use of unproven interventions outside of research. Ethics guidance for the COVID-19 pandemic, 25 June 2020 - PAHO\/WHO | Pan American Health Organization [Internet]. [cit\u00e9 11 ao\u00fbt 2023]. Disponible sur: https:\/\/www.paho.org\/en\/documents\/emergency-use-unproven-interventions-outside-research-ethics-guidance-covid-19-pandemic-0"},{"key":"12368_CR29","unstructured":"World Health Organization. Guidance for managing ethical issues in infectious disease outbreaks [Internet]. World Health Organization. 2016 [cit\u00e9 11 ao\u00fbt 2023]. 68 p. Disponible sur: https:\/\/apps.who.int\/iris\/handle\/10665\/250580"},{"key":"12368_CR30","unstructured":"Emergency use of. unproven clinical interventions outside clinical trials: ethical considerations [Internet]. [cit\u00e9 20 juin 2023]. Disponible sur: https:\/\/www.who.int\/publications-detail-redirect\/9789240041745"},{"key":"12368_CR31","unstructured":"Lamontagne F, Agarwal A, Rochwerg B, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for Covid-19. BMJ. 2020;370:m3379."},{"issue":"3","key":"12368_CR32","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s13181-020-00784-6","volume":"16","author":"AI Stolbach","year":"2020","unstructured":"Stolbach AI, Mazer-Amirshahi M, Marino R, Nelson LS, Sugarman J. ACMT position statement: Off-Label prescribing during COVID-19 pandemic. J Med Toxicol. 2020;16(3):342\u20135.","journal-title":"J Med Toxicol 1 Juill"},{"key":"12368_CR33","doi-asserted-by":"crossref","unstructured":"Kalil AC. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020;323(19):1897\u20138.","DOI":"10.1001\/jama.2020.4742"},{"issue":"11","key":"12368_CR34","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.1172\/JCI144186","volume":"130","author":"AL Caplan","year":"2020","unstructured":"Caplan AL, Waldstreicher J, Childers K, Maree A. Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies. J Clin Invest. 2020;130(11):5622\u20133.","journal-title":"J Clin Invest 2 Nov"},{"key":"12368_CR35","unstructured":"Clinical management of COVID-19 [Internet]. [cit\u00e9 28 nov 2025]. Disponible sur: https:\/\/www.who.int\/publications\/i\/item\/clinical-management-of-covid-19"},{"key":"12368_CR36","doi-asserted-by":"crossref","unstructured":"Ziemann S, Paetzolt I, Gr\u00fc\u00dfer L, Coburn M, Rossaint R, Kowark A. Poor reporting quality of observational clinical studies comparing treatments of COVID-19 \u2013 a retrospective cross-sectional study. BMC Med Res Methodol. 2022;22(1):23.","DOI":"10.1186\/s12874-021-01501-9"},{"key":"12368_CR37","unstructured":"Solidarity clinical trial for COVID. -19 treatments [Internet]. [cit\u00e9 11 ao\u00fbt 2023]. Disponible sur: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12368-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12368-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12368-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:34:59Z","timestamp":1768995299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12368-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12368"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12368-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing internests exist for the submitted work. Dr. Bosquet reports personal fees and non-financial support from Chugai Pharma France outside the submitted work. Dr. Affo reports non-financial support from Novartis outside the submitted work. Dr Versini reports no competing interests outside the submitted work. Dr Helfer reports no competing interests outside the submitted work. Dr. Happe reports personal fees from Bayer HealthCare SAS and non-financial support from Novartis Pharma SAS outside the submitted work. Dr. Mah\u00e9 reports grants from BMS Pfizer, grants from LEO Pharma, personal fees and non-financial support from BMS Pfizer, personal fees and non-financial support from Leo Pharma, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}